Long-Term Outcome of Drug-Coated Balloon vs Drug-Eluting Stent for Small Coronary Vessels
JACC: Cardiovascular Interventions · 2023-05 · 16 (9) · 1054-1061
DOI: 10.1016/j.jcin.2023.02.011 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023-05. Verfasst von Bernardo Cortese und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Ricerca e Innovazione Cardiovascolare, Milan, Italy; DCB Academy, Milano, Italy. Electronic address: bcortese@gmail.com. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Coronary Artery Disease, Myocardial Infarction, Vascular Diseases. Die Arbeit wurde bisher 119-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Native vessel coronary artery disease represents 1 of the most attractive fields of application for drug-coated balloons (DCBs). To date, several devices have been compared with drug-eluting stents (DESs) in this setting with different outcomes. OBJECTIVES: The authors sought to compare the short- and long-term performance of the paclitaxel DCB with the everolimus-eluting stent in patients with de novo lesions in small coronary vessel disease. METHODS: PICCOLETO II (Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment) was an academic, international, investigator-driven, multicenter, open-label randomized clinical trial in which patients were allocated to a DCB (n = 118) or DES (n = 114). We previously reported the superiority of DCBs regarding in-lesion late lumen loss at 6 months. Herein we report the final 3-year clinical follow-up with the occurrence of major adverse cardiac events (MACEs), a composite of cardiac death, nonfatal myocardial infarction, target lesion revascularization, and its individual components. RESULTS: The 3-year clinical follow-up (median 1,101 days; IQR: 1,055-1,146 days) was available for 102 patients allocated to DCB and 101 to DES treatment. The cumulative rate of all-cause death (4% vs 3.9%; P = 0.98), cardiac death (1% vs 1.9%; P = 0.56), myocardial infarction (6.9% vs 2%; P = 0.14), and target lesion revascularization (14.8% vs 8.8%; P = 0.18) did not significantly differ between DCBs and DESs. MACEs and acute vessel occlusion occurred more frequently in the DES group (20.8% vs 10.8% [P = 0.046] and 4% vs 0% [P = 0.042], respectively). CONCLUSIONS: The long-term clinical follow-up of the PICCOLETO II randomized clinical trial shows a higher risk of MACEs in patients with de novo lesions in small vessel disease when they are treated with the current-generation DES compared with the new-generation paclitaxel DCB. (Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment [PICCOLETO II]; NCT03899818).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fondazione Ricerca e Innovazione Cardiovascolare, Milan, Italy; DCB Academy, Milano, Italy. Electronic address: bcortese@gmail.com.
- Policlinico Universitario P. Giaccone, Palermo, Italy.
- Cardiology Department, Hospital Universitario de la Princesa, Universidad Autonoma de Madrid, Madrid, Spain.
- Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy.
Zitieren
APA
Cortese, B., Testa, G., Rivero, F., Erriquez, A., & Alfonso, F. (2023). Long-Term Outcome of Drug-Coated Balloon vs Drug-Eluting Stent for Small Coronary Vessels. JACC: Cardiovascular Interventions, 16(9), 1054-1061. https://doi.org/10.1016/j.jcin.2023.02.011
Vancouver
Cortese B, Testa G, Rivero F, Erriquez A, Alfonso F. Long-Term Outcome of Drug-Coated Balloon vs Drug-Eluting Stent for Small Coronary Vessels. JACC: Cardiovascular Interventions. 2023;16(9):1054-1061. doi:10.1016/j.jcin.2023.02.011
BibTeX
@article{Cortese2023,
author = {Cortese, Bernardo and Testa, Gabriella and Rivero, Fernando and Erriquez, Andrea and Alfonso, Fernando},
title = {Long-Term Outcome of Drug-Coated Balloon vs Drug-Eluting Stent for Small Coronary Vessels},
journal = {JACC: Cardiovascular Interventions},
year = {2023},
volume = {16},
number = {9},
pages = {1054--1061},
doi = {10.1016/j.jcin.2023.02.011}
}
EUVIMED